Pharma Sector Q2FY26 Preview: Challenges and Opportunities Ahead
Pharma Sector Q2FY26 Preview: Challenges and Opportunities Ahead The Indian pharma sector is expected to face a transition quarter in Q2FY26, with soft growth projected due to declining gRevlimid sales, GST-related de-stocking, and a weak acute season in India. Brokerages expect revenue growth to be in the range of 7-10% YoY, while earnings may rise […]